1,200 articles
Karen Cichowski
Karen Cichowski is an American cancer biologist and Harvard Medical School professor of medicine who studies how Ras signaling and the NF1 tumor suppressor drive cancer.
Karen H. Antman
Karen H. Antman is an American oncologist and hematologist known for the MAID regimen for advanced sarcoma, who served as Dean of Boston University's medical school from 2005 to 2024.
Karen H. Vousden
Karen H. Vousden is a British cancer researcher known for her work on the p53 tumor suppressor and MDM2, and director of the CRUK Beatson Institute in Glasgow.
Kari Alitalo
Kari Alitalo, born in 1952, is a Finnish physician-scientist at the University of Helsinki who discovered the VEGF-C/VEGFR-3 signaling pathway, key to lymphatic vessel growth and cancer metastasis research.
Kari Hemminki
Kari Hemminki, born 1947, is a Finnish cancer epidemiologist and geneticist who built the Swedish Family-Cancer Database and led cancer epidemiology at the German Cancer Research Center in Heidelberg.
Karim Fizazi
Karim Fizazi is a French medical oncologist specializing in prostate and genitourinary cancers, a professor at Paris-Saclay University who led landmark trials including LATITUDE, ARAMIS, and PEACE-1.
Karl-Henrik Robèrt
Karl-Henrik Robèrt is a Swedish physician and cancer researcher who founded The Natural Step in 1989 and co-developed the Framework for Strategic Sustainable Development, a planning method built on four sustainability principles.
Karla Kerlikowske
Karla Kerlikowske is an American physician-scientist, professor at the University of California, San Francisco, known for research on mammography screening and breast cancer risk prediction.
Katherine Jones (molecular biologist)
Katherine A. Jones is a molecular biologist and Professor Emerita at the Salk Institute, known for identifying P-TEFb, the elongation factor HIV Tat recruits, and for APC's repression of Wnt genes in colon cancer.
Katherine K. Matthay
Katherine K. Matthay is a pediatric hematologist-oncologist at UCSF who led the landmark CCG-3891 neuroblastoma trial, co-authored the INRG classification, and founded the NANT consortium.
Kathleen I. Pritchard
Kathleen I. Pritchard is a Canadian medical oncologist and clinical trials scientist at Sunnybrook in Toronto who chaired Canada's breast cancer trials group from 1984 to 2007.
Kathryn E. Wellen
Kathryn E. Wellen is an American cancer biologist who chairs Cancer Biology at the University of Pennsylvania's Perelman School of Medicine, known for linking cellular metabolism to histone acetylation.
Kathryn M. Ferguson
Kathryn M. Ferguson is a structural biologist and cancer researcher at Yale School of Medicine who studies how receptor tyrosine kinases, receptors driving many cancers, switch on and off.
Kathy D. Miller
Kathy D. Miller, also published as Kathy Miller, is an American medical oncologist at Indiana University School of Medicine who led the 2007 E2100 breast cancer trial.
Kathy S. Albain
Kathy S. Albain, also published as Kathy Albain, is an American medical oncologist and clinical-trial researcher at Loyola University Chicago, and since 2019 a vice chair of the SWOG Cancer Research Network.
Kazuhiko Nakagawa
Kazuhiko Nakagawa (中川 和彦) is a Japanese medical oncologist, director of the Cancer Center at Kindai University Hospital, known for leading RELAY, the first global lung cancer trial led by a Japanese principal investigator.
Keiichi I. Nakayama
Keiichi I. Nakayama (中山敬一) is a Japanese cancer biologist at Kyushu University and Institute of Science Tokyo known for p27 knockout mice and ubiquitin ligases.
Keith T. Flaherty
Keith T. Flaherty is an American medical oncologist who directs clinical cancer research at Mass General Cancer Center and pioneered targeted therapies for melanoma, including vemurafenib.
Ken Chen
Ken Chen is a computational biologist and Professor of Bioinformatics and Computational Biology at the University of Texas MD Anderson Cancer Center, known for widely used cancer genomics tools including BreakDancer, VarScan, and Monovar.
Ken S. Lau
Ken S. Lau (Ken Lau) is a molecular biologist at Vanderbilt University School of Medicine who studies how colorectal cancer begins and evolves using single-cell and spatial mapping.
Kenneth Carl Anderson
Kenneth Carl Anderson is an American hematologist-oncologist and multiple myeloma researcher who directs the Jerome Lipper Multiple Myeloma Center at Dana-Farber and led preclinical work on bortezomib, FDA-approved in 2003.
Kevin C. Oeffinger
Kevin C. Oeffinger is an American family physician and cancer survivorship researcher, professor at the Duke Cancer Institute and founding director of its Center for Onco-Primary Care.
Kevin Jones (orthopaedic surgeon)
Kevin B. Jones is a professor of orthopaedics at the University of Utah and an investigator at Huntsman Cancer Institute who studies the molecular biology of synovial sarcoma.
Kevin Litchfield
Kevin Litchfield is a cancer genomics and precision oncology researcher who leads the TIGI laboratory at the UCL Cancer Institute, studying why some patients respond to immunotherapy.
Kevin Shannon
Kevin M. Shannon is an American pediatric hematologist-oncologist at the University of California, San Francisco, known for showing that the NF1 gene acts as a tumor suppressor in childhood myeloid leukemia.
Kevin Struhl
Kevin Struhl (born 1952) is an American molecular biologist at Harvard Medical School known for work on transcriptional regulation and an epigenetic switch linking inflammation to cancer.
Khandan Keyomarsi
Khandan Keyomarsi is a cancer biologist and professor of experimental radiation oncology at MD Anderson Cancer Center, known for linking low-molecular-weight cyclin E to breast cancer prognosis.
Kimberly Stegmaier
Kimberly Stegmaier is an American pediatric oncologist and cancer biologist who chairs pediatric oncology at Dana-Farber Cancer Institute and studies therapeutic targets in childhood leukemias and solid tumors.
Kjell Öberg
Kjell Öberg is a Swedish physician-scientist and professor emeritus at Uppsala University who founded its endocrine oncology department, pioneered interferon treatment of carcinoid syndrome, and co-founded ENETS.
Klaus Pantel
Klaus Pantel, born 1960, is a German physician and oncologist directing the Institute of Tumor Biology in Hamburg, known for research on disseminated tumor cells.